{"id":2834,"date":"2020-09-11T14:15:00","date_gmt":"2020-09-11T14:15:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/"},"modified":"2020-09-11T14:15:00","modified_gmt":"2020-09-11T14:15:00","slug":"notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/","title":{"rendered":"Notice to attend the Extraordinary General Meeting in XVIVO Perfusion AB (publ)"},"content":{"rendered":"
\n

The shareholders of XVIVO Perfusion AB (publ), corporate identity number 556561-0424 (\u201cthe Company\u201d), are hereby invited to attend the Extraordinary General Meeting of shareholders on Wednesday October 14, 2020 at 16.00 in the Company\u2019s offices at M\u00e4ssans gata 10 in Gothenburg, Sweden.<\/p>\n

Registration<\/strong><\/p>\n

Shareholders who wish to attend the Extraordinary General Meeting (\u201cEGM\u201d) must:
– be entered in their own name (not through a nominee shareholder) in the registry of shareholders maintained by Euroclear Sweden AB (\u201cEuroclear\u201d) on Tuesday October 6, 2020 and,
–\u00a0notify their attendance so that the Company is in receipt thereof no later than Friday October 9, 2020. Notification of attendance shall be sent to Kristoffer Nordstr\u00f6m, either in writing to XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Gothenburg, Sweden (mark the envelope EGM 2020), by telephone +46 735-19 21 64, by fax +46 31 788 21 69, or by e-mail to kristoffer.nordstrom@xvivoperfusion.com.<\/p>\n

When notifying, shareholders should state their full name and preferably their personal identity number, or corporate identity number (or the equivalent), address, telephone number, registered shareholding, details of any advisors (no more than two), and where appropriate, details of a representative or proxy. For shareholders who are represented by another party, the original of a proxy, signed and dated by the shareholder, should be sent together with the notification. Proxy and postal ballot forms are available at www.xvivoperfusion.com. Any party representing a legal entity must produce a witnessed copy of the certificate of incorporation, or equivalent authorization documents, showing the authorized signatory for the company.<\/p>\n

In order to be entitled to attend the EGM, shareholders whose shares are registered through a bank, a private securities broker, or any other nominee, must temporarily re-register their shares in their own name in the share register maintained by Euroclear. In order for such re-registration to be entered in the register of shareholders by Tuesday October 6, 2020, shareholders should well in advance before this date, instruct their nominees to effect such a re-registration.<\/p>\n

With regard to the current situation surrounding the Coronavirus, the Board has decided to enable its shareholders to exercise their votes through postal ballot in accordance with \u00a7 3 of the law (2020:198) regarding temporary exceptions to facilitate annual general meetings of corporations and associations. Postal ballot forms are available at the Company\u2019s website, www.xvivoperfusion.com, in connection with the notice to attend.<\/p>\n

Proposed agenda<\/strong>
1.\u00a0Opening of the meeting
2.\u00a0Election of the chairman for the meeting
3.\u00a0Preparation and approval of the voting list
4.\u00a0Approval of the agenda.
5.\u00a0Election of one or two persons to verify the minutes together with the chairman
6.\u00a0Consideration of whether the meeting has been duly convened
7.\u00a0Resolution on the number of Board members
8.\u00a0The Nomination Committee presents its proposal to elect new Board members
9.\u00a0Election of new Board members
a.\u00a0Lena H\u00f6glund
b.\u00a0Lars Henriksson
10.\u00a0Resolution on total remuneration to the Board
11.\u00a0Closing of the meeting<\/p>\n

Proposals of the Nomination Committee<\/strong><\/p>\n

Chairman of the meeting (item 2)<\/strong>
The Nomination Committee proposes the lawyer Olof Thorsell as chairman of the meeting.<\/p>\n

Resolution on the number of Board members (item 7)<\/strong>
The Nomination Committee proposes that the Board, for the time until the next General Meeting, shall comprise of six Board members and no deputies.<\/p>\n

Election of new Board members (item 9 a-b)<\/strong>
Further, the Nomination Committee proposes election of Lena H\u00f6glund and Lars Henriksson as new members of the Board. In connection with this, Dag Andersson resigns from the Board. A presentation of the proposed Board members, together with the Nomination Committee\u2019s motivated opinion, will be made available at the Company\u2019s website www.xvivoperfusion.com in connection with the publication of this notice to attend.<\/p>\n

Resolution on total remuneration to the Board (item 10)<\/strong>
Lastly, the Nomination Board proposes that the total remuneration to the Board of the Company, is increased with SEK 87,500. Remuneration to above proposed Board members will follow the remuneration levels for Board and Committee members as decided by the Annual General Meeting on Tuesday March 31, 2020 (\u00a7 12 of the minutes of the General Meeting), which means that each of the proposed Board members will receive a yearly remuneration of SEK 175,000. Said remuneration will be proportionate to the respective term served by the Board member. The total remuneration to the board for the term period exceeds the total remuneration to the Board of 1,005,000, decided on by the General Meeting, with SEK 87,500.<\/p>\n

Processing of personal data<\/strong>
For information on how your personal data is processed in connection with the Extraordinary General Meeting, see https:\/\/www.euroclear.com\/dam\/ESw\/Legal\/Integritetspolicy-bolagsstammor-svenska.pdf<\/a> and https:\/\/www.xvivoperfusion.com\/corporate\/privacy-policy\/<\/a>.<\/p>\n

Miscellaneous<\/strong>
The proxy and postal ballot forms will be available at the Company\u2019s offices and on the Company\u2019s website www.xvivoperfusion.com no later than 3 weeks before the EGM. The documents will be sent to shareholders free of charge upon request, provided that the shareholders state their address. The documents will also be available at the EGM.<\/p>\n

At the time of the issue of this notice, the total number of shares and votes in the Company amounts to 26\u00a0600 496, all being the same class of shares. The Company does not hold any treasury shares.<\/p>\n

Shareholders have the right to ask the Board and CEO questions at the EGM about the Company, the Company\u2019s financial position and about the items and proposals which will be dealt with at the EGM.<\/p>\n

Gothenburg, September 2020
XVIVO Perfusion AB (publ)
The Board<\/p>\n

This is a translation of the Swedish version of the notice to attend the EGM. When in doubt, the Swedish wording prevails.<\/em><\/p>\n<\/div>\n

\n

For further information please contact:<\/strong><\/p>\n\n

Christoffer Rosenblad, CFO, +46 73 519 21 59 e-post: christoffer.rosenblad@xvivoperfusion.com<\/a>
Dag Andersson, CEO, +46 76 643 30 31, e-post: dag.andersson@xvivoperfusion.com<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong><\/p>\n\n

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.<\/a><\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n\n

Notice to attend the Extraordinary General Meeting in XVIVO Perfusion AB (publ)<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The shareholders of XVIVO Perfusion AB (publ), corporate identity number 556561-0424 (\u201cthe Company\u201d), are hereby invited to attend the Extraordinary…<\/p>\n","protected":false},"template":"","class_list":["post-2834","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-gm","mfn-news-tag-mfn-ci-gm-notice"],"acf":[],"yoast_head":"\nNotice to attend the Extraordinary General Meeting in XVIVO Perfusion AB (publ) - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notice to attend the Extraordinary General Meeting in XVIVO Perfusion AB (publ) - XVIVO\" \/>\n<meta property=\"og:description\" content=\"The shareholders of XVIVO Perfusion AB (publ), corporate identity number 556561-0424 (\u201cthe Company\u201d), are hereby invited to attend the Extraordinary...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\\\/\",\"name\":\"Notice to attend the Extraordinary General Meeting in XVIVO Perfusion AB (publ) - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2020-09-11T14:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice to attend the Extraordinary General Meeting in XVIVO Perfusion AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice to attend the Extraordinary General Meeting in XVIVO Perfusion AB (publ) - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/","og_locale":"en_US","og_type":"article","og_title":"Notice to attend the Extraordinary General Meeting in XVIVO Perfusion AB (publ) - XVIVO","og_description":"The shareholders of XVIVO Perfusion AB (publ), corporate identity number 556561-0424 (\u201cthe Company\u201d), are hereby invited to attend the Extraordinary...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/","name":"Notice to attend the Extraordinary General Meeting in XVIVO Perfusion AB (publ) - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2020-09-11T14:15:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/notice-to-attend-the-extraordinary-general-meeting-in-xvivo-perfusion-ab-publ\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Notice to attend the Extraordinary General Meeting in XVIVO Perfusion AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}